Clinical PictureLeopard-like vitiligo with capecitabine
References (0)
Cited by (14)
Adverse cutaneous reactions to chemotherapeutic drugs
2020, Clinics in DermatologyCitation Excerpt :Similar to NEH, the pathogenesis of ESS is obscure and complicated by its association with targeted therapies that are not conventionally understood to result in direct cytotoxicity; nonetheless, the distribution and histologic findings of both ESS and NEH suggest accumulation, and/or concentrating effects are likely related to the pathogenic cascade. A wide variety of pigmentary alterations are seen with chemotherapeutics (Table 3).2,7,90,93–95,97–99 These alterations range not only by pigmentary pattern (depigmentation vs hyperpigmentation) but also distribution (localized vs diffuse; predominating in the skin, nails, mucosal surfaces, or hair follicles).
Pigmentary disorders induced by anticancer agents. Part I: Chemotherapy
2013, Annales de Dermatologie et de VenereologieChemotherapeutic agents and the skin: An update
2008, Journal of the American Academy of DermatologyCitation Excerpt :Chemotherapy-induced inflammation of actinic keratoses was first described in 1962 with the use of systemic fluorouracil, but had never before been linked to capecitabine therapy.217 Other capecitabine-induced cutaneous adverse events described in single case reports include cutaneous and mucosal hyperpigmentation, spotty, “leopard-like” repigmentation of vitiligo in sun-exposed sites,218 radiation recall dermatitis, onycholysis, and onychomadesis.210,219 Tegafur is a prodrug of 5-FU that is given orally.
A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient
2022, Journal of Oncology Pharmacy PracticeFixed drug eruption late in the course of capecitabine therapy
2016, Connecticut Medicine